Skip to content

Treatment of severe immune thrombocytopenia with hormone resistance by combination of traditional Chinese and Western Medicine

Treatment of severe immune thrombocytopenia with hormone resistance by combination of traditional Chinese and Western Medicine

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037645
Enrollment
Unknown
Registered
2020-08-29
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune thrombocytopenia

Interventions

Sponsors

Shanghai Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Aged 18-80 years old male and female; (2) Patients with ITP who were treated with glucocorticoid for more than 4 weeks met the diagnostic standard of "Chinese expert consensus on diagnosis and treatment of adult primary immune thrombocytopenia (Revised Edition) (2018), and TCM syndrome differentiation belongs to Qi and yin deficiency type; (3) Two consecutive platelet tests (not detected in the same day) <= 20 x 10^9/L; (4) Those who voluntarily sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Although it meets the diagnostic criteria of Western medicine, TCM syndrome is not Yin deficiency type; (2) Patients with history of thrombosis; (3) HBV, HCV, HIV carriers or patients; (4) Allergic constitution or allergic to a variety of drugs; (5) Pregnant or lactating women; (6) Patients with a history of mental illness; (7) Suspected or confirmed history of alcohol and drug abuse; (8) Severe abnormal function of heart, lung, liver and kidney; (9) Severe or uncontrollable infection; (10) Those who took other traditional Chinese medicine or participated in other clinical trials in recent 4 weeks; (11) Any other circumstances in which the investigator believes that the patient should not participate in this study.

Design outcomes

Primary

MeasureTime frame
routine blood test;Bone marrow examination;

Secondary

MeasureTime frame
Expression of P-gp in CD19+, CD4+;

Countries

China

Contacts

Public ContactWenwen Jiang

Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of TCM

2504866135@qq.com+86 15000127167

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026